MX2023001274A - Sintesis quiral de inhibidores de raf biciclicos fusionados. - Google Patents

Sintesis quiral de inhibidores de raf biciclicos fusionados.

Info

Publication number
MX2023001274A
MX2023001274A MX2023001274A MX2023001274A MX2023001274A MX 2023001274 A MX2023001274 A MX 2023001274A MX 2023001274 A MX2023001274 A MX 2023001274A MX 2023001274 A MX2023001274 A MX 2023001274A MX 2023001274 A MX2023001274 A MX 2023001274A
Authority
MX
Mexico
Prior art keywords
fused bicyclic
chiral synthesis
raf inhibitors
tautomer
stereoisomer
Prior art date
Application number
MX2023001274A
Other languages
English (en)
Inventor
Steven Christopher Glossop
Clifford David Jones
Andrew Belfield
Neil Hawkins
Jean - François Margathe
Chiara Colletto
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2023001274A publication Critical patent/MX2023001274A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/821—Ruthenium

Abstract

La presente descripción en general se refiere a la síntesis mejorada de enantiómeros inhibidores de Raf bicíclicos fusionados de fórmula (I), (Ia), (Ib), (II), (IIa), o (IIb), o una sal, tautómero, o estereoisómero del mismo farmacéuticamente aceptable, con alto exceso enantiomérico (% de ee). La descripción también se refiere a un método para usar el compuesto de fórmula (I), (Ia), (Ib), (II), (IIa), o (IIb), o una sal, tautómero, o estereoisómero del mismo farmacéuticamente aceptable, para tratar enfermedades tales como cáncer, que incluye cáncer colorrectal.
MX2023001274A 2020-07-28 2021-07-28 Sintesis quiral de inhibidores de raf biciclicos fusionados. MX2023001274A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063057531P 2020-07-28 2020-07-28
PCT/EP2021/071219 WO2022023450A1 (en) 2020-07-28 2021-07-28 Chiral synthesis of fused bicyclic raf inhibitors

Publications (1)

Publication Number Publication Date
MX2023001274A true MX2023001274A (es) 2023-04-24

Family

ID=77564067

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001274A MX2023001274A (es) 2020-07-28 2021-07-28 Sintesis quiral de inhibidores de raf biciclicos fusionados.

Country Status (10)

Country Link
US (1) US20220041595A1 (es)
EP (1) EP4188923A1 (es)
JP (1) JP2023535595A (es)
KR (1) KR20230058630A (es)
CN (1) CN116348465A (es)
AU (1) AU2021318923A1 (es)
CA (1) CA3187393A1 (es)
IL (1) IL300110A (es)
MX (1) MX2023001274A (es)
WO (1) WO2022023450A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188552A2 (en) 2020-07-28 2023-06-07 Jazz Pharmaceuticals Ireland Limited Fused bicyclic raf inhibitors and methods for use thereof
CN114921508B (zh) * 2022-07-22 2022-10-11 常熟药明康德新药开发有限公司 (r)-6-羟基色满-3-羧酸的生物催化制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932657A (en) 1973-11-12 1976-01-13 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome encapsulation of chelating agents
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
JPS6058915A (ja) 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4830858A (en) 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
JPH0617309B2 (ja) 1985-11-29 1994-03-09 株式会社ビタミン研究所 アドリアマイシン包埋リポソ−ム製剤
DE3611229A1 (de) 1986-04-04 1987-10-08 Basf Ag Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinoidpraeparaten
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
CA2184242C (en) 1994-02-28 2000-05-02 Jorg Kreuter Drug targeting system, method for preparing same and its use
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
AU5557796A (en) 1995-04-18 1996-11-07 Dehlinger, Peter J. Liposome drug-loading method and composition
US8137699B2 (en) 2002-03-29 2012-03-20 Trustees Of Princeton University Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
TWI235066B (en) 2001-10-03 2005-07-01 Celator Technologies Inc Liposome loading with metal ions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ES2387886T3 (es) 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
SI2653465T1 (sl) * 2004-03-15 2016-10-28 Janssen Pharmaceutica N.V. Modulatorji opiodnih receptorjev
EP1885688B1 (en) * 2005-05-20 2010-09-22 Dr. Reddy's Laboratories (EU) Limited Asymmetric hydrogenation for the preparation of diphenylalanine derivatives
GB201416186D0 (en) * 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
CN109503659B (zh) * 2019-01-03 2021-06-18 凯特立斯（深圳）科技有限公司 氧杂螺环双膦配体及其在α,β-不饱和羧酸不对称氢化中的应用

Also Published As

Publication number Publication date
CN116348465A (zh) 2023-06-27
KR20230058630A (ko) 2023-05-03
IL300110A (en) 2023-03-01
US20220041595A1 (en) 2022-02-10
AU2021318923A1 (en) 2023-03-09
JP2023535595A (ja) 2023-08-18
EP4188923A1 (en) 2023-06-07
CA3187393A1 (en) 2022-02-03
WO2022023450A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
TN2018000319A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
MX2022007969A (es) Inhibidores de egfr.
MX2023001274A (es) Sintesis quiral de inhibidores de raf biciclicos fusionados.
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
MX2022000271A (es) Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos.
SG10201903532XA (en) 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MY155653A (en) Triazine compounds as p13 kinase and mtor inhibitors
MY147440A (en) Process for making 3-substituted 2-amino-5-halobenzamides
MX2021013531A (es) Inhibidores de cdk.
MX2022005708A (es) Sintesis mejorada del compuesto inhibidor de g12c de kras.
NZ710411A (en) Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
SG170739A1 (en) Iap bir domain binding compounds
TW200800990A (en) Azaindole inhibitors of aurora kinases
IN2014KN01030A (es)
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
MX2012001420A (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.
EA201891437A1 (ru) Способ разделения энантиомеров пиперазиновых производных
SG11201900298RA (en) Heterocyclic compound used as fgfr inhibitor
UA107002C2 (uk) Етинільні похідні
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
MX2023005884A (es) Metodos para sintetizar compuestos de piridinona-piridinilo sustituidos.
TW200635905A (en) Processes for producing 4-aminoquinazolines
MX2010001229A (es) Procedimiento para la resolucion de zopiclona y compuestos intermedios.